Coronavirus (COVID-19) News
Filter News
Found 2,648 articles
-
Third-quarter revenues for antiviral treatment Paxlovid dropped 97% operationally compared with the prior-year period, while vaccine Comirnaty revenues declined 70% in the quarter.
-
Strategies Behind Near-Zero COVID-19 Incidence in NBA "Bubble" Published in ADLM's The Journal of Applied Laboratory Medicine
10/30/2023
A report published in the Association for Diagnostics & Laboratory Medicine's The Journal of Applied Laboratory Medicine describes the strategies used by the National Basketball Association to limit COVID-19 exposure among the individuals who participated in the 2019–2020 season.
-
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
10/26/2023
Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
-
New Hope for Long COVID Sufferers
10/25/2023
COVID is an acute disease that comes and goes, but for a growing number of people, the sequelae to the infection - the aftereffects - can become a constellation of symptoms called long COVID that may affect sufferers for years, if not a lifetime.
-
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
10/24/2023
GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced an update on key strategic initiatives.
-
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
10/24/2023
Moderna, Inc. announced that the first participant has been dosed in a Phase 3 study of the Company's combination vaccine candidate against influenza and COVID-19 in the U.S. The trial is expected to enroll approximately 8,000 adults in the Northern Hemisphere.
-
GeNeuro and Verily Collaborate to Advance Long-COVID Research
10/19/2023
GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an Alphabet precision health technology company, to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein in SARS-CoV-2 infection.
-
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
10/16/2023
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission on Friday, October 13, 2023.
-
Hyundai Bioscience announces that "Xafty is the only antiviral that can be immediately used for the treatment of Dengue fever"
10/13/2023
Hyundai Bioscience announced that Xafty™, a broad-spectrum antiviral drug, can solve RNA virus infections, capable of treating both COVID-19 and Dengue fever or Dengue virus infection".
-
Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023
10/11/2023
Codagenix Inc. announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.
-
Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine
10/3/2023
Codagenix Inc. announced that the BARDA has entered into a contract with Codagenix to support the costs of a Phase 2b clinical study of CoviLiv™ for the prevention of symptomatic COVID-19 in people who have completed their primary approved/authorized COVID-19 vaccine series and their last COVID-19 vaccine was at least 3 months beforehand.
-
The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.
-
UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination
9/21/2023
In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.
-
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
9/19/2023
Biophytis SA announced that it has received a response from the French National Authority for Health to its request for Early Access Authorization in France for patients suffering from severe forms of COVID-19 and provides an update on its strategy in other countries.
-
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
9/14/2023
BIOXYTRAN, INC. announced that its preprint article titled “Evaluation of Complex Carbohydrates Showing Broad-Spectrum Antiviral Activity Against SARS-CoV-2, Influenzas-a, and Human Respiratory Syncytial Virus Strain A2 in ‘In Vitro’ Setting” contains data showing a significant reduction of viral load in COVID-19, influenza and in human Respiratory Syncytial Virus.
-
The company plans to launch up to 15 new products and bring up to 50 new candidates to the clinic over the next five years as part of its growth plan, while scaling down COVID-19 manufacturing.
-
Health Canada authorizes Moderna COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant
9/12/2023
Health Canada has authorized the use of the Moderna SPIKEVAX™ COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for people six months of age and older.
-
The regulator Monday approved the companies’ supplemental Biologics License Applications for their respective mRNA shots formulated to more closely target currently circulating variants.
-
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
9/11/2023
Sinovac Biotech Ltd. announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
-
IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease
9/7/2023
Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., announced the upcoming presentation of new data at IDWeek 2023 on its investigational oral antiviral for COVID-19, ensitrelvir, and Fetroja®, an antibiotic marketed under the brand name Fetcroja® in Europe.